Similar articles

• Ca2+ channel subtypes and pharmacology in the kidney.

  Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Hayashi K, et al. Circ Res. 2007 Feb 16;100(3):342-53. doi: 10.1161/01.RES.0000256155.31133.49. Circ Res. 2007. PMID: 17307972 Review.
• Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.

  Baylis C, Qiu C, Engels K. Baylis C, et al. Am J Kidney Dis. 2001 Dec;38(6):1292-7. doi: 10.1053/ajkd.2001.29227. Am J Kidney Dis. 2001. PMID: 11728963
• [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].

  Richard S, Virsolvy A, Fort A. Richard S, et al. Ann Cardiol Angeiol (Paris). 2008 Jun;57(3):166-73. doi: 10.1016/j.ancard.2008.02.019. Epub 2008 Jun 4. Ann Cardiol Angeiol (Paris). 2008. PMID: 18565491 Review. French.
• [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers].

  Kimura G. Kimura G. Clin Calcium. 2010 Jan;20(1):94-9. Clin Calcium. 2010. PMID: 20048440 Review. Japanese.
• [New calcium channel blockers for the treatment of hypertension].

  Tamargo J. Tamargo J. Hipertens Riesgo Vasc. 2017;34 Suppl 2:5-8. doi: 10.1016/S1889-1837(18)30067-9. Hipertens Riesgo Vasc. 2017. PMID: 29908667 Spanish.